Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

774 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.
Le Moing V, Chêne G, Leport C, Lewden C, Duran S, Garré M, Masquelier B, Dupon M, Raffi F; Antiprotéases Cohorte (APROCO) Study Group. Le Moing V, et al. Among authors: chene g. Clin Infect Dis. 2002 Jan 15;34(2):239-47. doi: 10.1086/324354. Epub 2001 Dec 4. Clin Infect Dis. 2002. PMID: 11740714
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy.
Savès M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, Chêne G; Antiprotéases Cohorte (APROCO) Study Group. Savès M, et al. Among authors: chene g. Clin Infect Dis. 2002 May 15;34(10):1396-405. doi: 10.1086/339866. Epub 2002 Apr 22. Clin Infect Dis. 2002. PMID: 11981737
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group. de Lédinghen V, et al. Among authors: chene g. J Hepatol. 2002 May;36(5):672-80. doi: 10.1016/s0168-8278(02)00026-0. J Hepatol. 2002. PMID: 11983451 Clinical Trial.
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V, Trimoulet P, Winnock M, Bernard PH, Bourlière M, Portal I, Rémy AJ, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P; French Multicenter Study Group. de Lédinghen V, et al. Among authors: chene g. J Hepatol. 2002 Jun;36(6):819-26. doi: 10.1016/s0168-8278(02)00071-5. J Hepatol. 2002. PMID: 12044534 Clinical Trial.
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.
Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Egger M, et al. Among authors: chene g. Lancet. 2002 Jul 13;360(9327):119-29. doi: 10.1016/s0140-6736(02)09411-4. Lancet. 2002. PMID: 12126821
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study.
Lewden C, Raffi F, Cuzin L, Cailleton V, Vildé JL, Chêne G, Allavena C, Salamon R, Leport C. Lewden C, et al. Among authors: chene g. J Infect Dis. 2002 Sep 1;186(5):710-4. doi: 10.1086/342047. Epub 2002 Jul 29. J Infect Dis. 2002. PMID: 12195361 Clinical Trial.
774 results